Obesity & Diabetes Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity & Diabetes Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Type 2 Diabetes
Study: LANTUS allows more patients to achieve treatment success compared to NPH
November 24th, 2003
Aventis announced that newly published data demonstrate that type 2 diabetes patients treated with the 24-hour basal insulin analogue LANTUS (insulin glargine [rDNA origin] injection) achieved greater complete treatment success, rigorously defined as reaching target A1C<7% without an episode of documented nocturnal hypoglycemia, compared to those treated with neutral protamine hagedorn (NPH). The U.S.-based study, called Treat-to-Target, will be published in the November issue of Diabetes Care. The study included 756 people with type 2 diabetes who were previously inadequately controlled on one or two oral agents. Patients were treated with...
Source: Obesity & Diabetes Week (2003-11-24)
|
